同种异体人间充质干细胞静脉输注治疗特发性肺纤维化的I期安全性临床试验(AETHER)
AETHER试验是首个评估单次静脉输注骨髓来源间充质干细胞治疗特发性肺纤维化(IPF)安全性的研究。9例轻中度IPF患者依次接受20、100或200×10^6个细胞的单次输注,主要终点为输注后4周内治疗相关严重不良事件的发生率,未报告此类事件;至60周,用力肺活量占预计值百分比平均下降3.0%,一氧化碳弥散量占预计值百分比平均下降5.4%。
要点
- 单次静脉输注骨髓间充质干细胞在轻中度IPF患者中未出现治疗相关严重不良事件。
- 2例死亡与疾病进展相关,判定为非治疗相关。
- 至60周,FVC%pred平均下降3.0%,DLCO%pred平均下降5.4%。
核心结论
- 单次静脉输注人间充质干细胞在轻中度IPF患者中具有安全性支持证据。
研究设计与样本
- I期安全性临床试验,9例轻中度IPF患者依次分配至3个队列。
- 单次静脉输注年轻无关男性供者骨髓来源间充质干细胞,剂量为20、100或200×10^6个/次。
主要发现
- 未报告治疗相关严重不良事件(复合终点包括死亡、非致命性肺栓塞、卒中、因呼吸困难加重住院及有临床意义的实验室检查异常)。
- 2例死亡与IPF进展(疾病恶化或急性加重)相关,判定为非治疗相关。
- 输注后60周,FVC占预计值百分比平均下降3.0%,DLCO占预计值百分比平均下降5.4%。
关键数值与推荐
- 主要终点为输注后第4周治疗相关严重不良事件的发生率。
- 安全性评估持续至第60周,并额外延长28天。
- 次要疗效终点为探索性,评估疾病进展。
临床怎么用
- 该I期试验提示单次静脉输注间充质干细胞在轻中度IPF中安全性可接受,但疗效尚需进一步研究。
局限性
- 样本量小(9例),为I期安全性试验,未设对照组,疗效终点为探索性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite Food and Drug Administration approval of 2 new drugs for idiopathic pulmonary fibrosis (IPF), curative therapies remain elusive and mortality remains high. Preclinical and clinical data support the safety of human mesenchymal stem cells as a potential novel therapy for this fatal condition. The Allogeneic Human Cells (hMSC) in patients with Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER) trial was the first study designed to evaluate the safety of a single infusion of bone marrow-derived mesenchymal stem cells in patients with idiopathic pulmonary fibrosis. METHODS: Nine patients with mild to moderate IPF were sequentially assigned to 1 of 3 cohorts and dosed with a single IV infusion of 20, 100, or 200 × 106 human bone marrow-derived mesenchymal stem cells per infusion from young, unrelated, men. All baseline patient data were reviewed by a multidisciplinary study team to ensure accurate diagnosis. The primary end point was the incidence (at week 4 postinfusion) of treatment-emergent serious adverse events, defined as the composite of death, nonfatal pulmonary embolism, stroke, hospitalization for worsening dyspnea, and clinically significant laboratory test abnormalities. Safety was assessed until week 60 and additionally 28 days thereafter. Secondary efficacy end points were exploratory and measured disease progression. RESULTS: No treatment-emergent serious adverse events were reported. Two nontreatment-related deaths occurred because of progression of IPF (disease worsening and/or acute exacerbation). By 60 weeks postinfusion, there was a 3.0% mean decline in % predicted FVC and 5.4% mean decline in % predicted diffusing capacity of the lungs for carbon monoxide. CONCLUSIONS: Data from this trial support the safety of a single infusion of human mesenchymal stem cells in patients with mild-moderate IPF. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02013700; URL: www.clinicaltrials.gov.
引用
- Glassberg MK, Minkiewicz J, Toonkel RL, et al. Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial. Chest. 2016. PMID: 27890713. doi:10.1016/j.chest.2016.10.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。